Myriad Genetics, Clairity, and MagView announced a partnership to launch an integrated AI‑and‑genetic risk platform for breast health. The collaboration combines Myriad’s MyRisk Hereditary Cancer Test, Clairity’s FDA‑authorized AI‑powered breast cancer risk assessment (Clairity Breast), and MagView’s Luminary Risk workflow platform into a single, clinician‑friendly tool.
The platform will feed genetic data from MyRisk, imaging‑derived risk scores from Clairity Breast, and workflow orchestration from MagView’s Luminary Risk system. Clairity Breast, which received de novo FDA authorization on May 30 2025, predicts five‑year breast cancer risk from routine mammograms, while MyRisk provides hereditary cancer testing that has grown 14% year‑over‑year in Q2 2025 and 11% in Q3 2025. MagView’s software already supports risk assessment programs in more than 2,500 U.S. facilities.
Strategically, the partnership aligns with Myriad’s Cancer Care Continuum, which seeks to integrate hereditary testing, companion diagnostics, and risk management. By combining genetic and imaging data, the platform offers a more comprehensive risk profile than age or family history alone, potentially improving early detection and personalized intervention. Clairity’s FDA approval gives the AI component a regulatory edge in a market that is projected to reach $63 billion.
Myriad’s Q3 2025 earnings provide context for the partnership. Revenue fell 4% to $205.7 million, but the company beat analyst expectations by $0.24 million and reported an adjusted EBITDA of $10.3 million, a significant beat over the $5.57 million forecast. The revenue decline was driven by a 4% drop in legacy product sales, while hereditary cancer testing volumes grew 11% YoY, offsetting headwinds. The company reaffirmed its full‑year 2025 revenue guidance of $818–$828 million.
CEO Sam Raha highlighted the partnership’s potential to empower clinicians: “We are giving providers a unified, actionable view of risk that can enable earlier, more personalized interventions.” Jeff Luber, Clairity CEO, added that integrating with MagView and Myriad “provides a more complete and actionable view of risk than can be achieved using age and family history alone.” Bryan Chapin, MagView CEO, noted the workflow efficiency gains that the platform will deliver to providers.
Commercial details such as the commercial launch date, pricing, and revenue‑sharing terms have not been disclosed. The companies have indicated that the integrated solution will be available to clinicians and patients in the near term, but no specific timeline or pricing model has been announced.
The partnership positions Myriad to capture a larger share of the breast cancer risk assessment market, potentially translating into incremental revenue from both genetic testing and AI‑driven imaging analysis. By offering a unified platform, the companies aim to reduce administrative burden for providers while improving risk stratification, which could enhance patient outcomes and strengthen Myriad’s competitive stance in the precision‑medicine space.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.